Newly Diagnosed Peripheral T-cell Lymphoma Clinical Trial
Official title:
Prospective, Single Arm, Single Center Study of Duvelisib Combined With Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma (PTCL)
This is a prospective, single arm, single center study to evaluate the efficacy and safety of Duvelisib combined with Chidamide in the treatment of newly diagnosed peripheral T-cell lymphoma.
This is a prospective, single arm, single center study, including two phases. It plans to recruit36 patients with clinically diagnosed primary PTCL who will be treated with Duvelisib and Chidamide. In the first phase Duvelisib is Oral administration at a dose of 25mg twice a day, and every 4 weeks (28 days) was a cycle. Next administration will be depend on whether the efficacy reaches CR in the second phase. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03631862 -
Treatment of Newly Diagnosed Peripheral T-cell Lymphoma
|
Phase 4 | |
| Recruiting |
NCT05896813 -
CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma
|
N/A | |
| Recruiting |
NCT05931263 -
A Randomized Clinical Trial Comparing Chi-BEAM With BEAM Regimen Combined With ASCT for the Treatment of ND PTCL
|
Phase 3 |